Articles tagged "Immunosuppression"

2018 American Transplant Congress
Automated Systems to Identify and Address Adherence Barriers Result in Sustained Reduction of Late Allograft Rejection
D. Hooper, C. Varnell, Jr., K. Rich, J. Huber, D. Dahale, A. Carle, A. Pai, A. Modi.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Background: Patient-identified barriers to taking immunosuppressive medications are associated with rejection and allograft loss, yet interventions targeting adherence barriers are rarely integrated into clinical practice.…
2018 American Transplant Congress
Sirolimus-Based, Prednisone-Free Regimen in Kidney Transplantation: Long Term Results of an Open-Label, Randomized Controlled Trial
A. Shetty,¹ B. Ho,¹ V. Mas,² Y. Kassis,¹ S. Park,¹ J. Leventhal,¹ D. Chhabra,³ L. Gallon.¹
¹Northwestern University, Chicago; ²University of Virginia, Charlottesville; ³Advocate Christ Medical Center, Chicago.
Background: Calcineurin (CNI) nephrotoxicity is implicated in chronic allograft dysfunction and presents an argument for CNI minimizing immunosuppression. We assessed the long-term effects of CNI…
2018 American Transplant Congress
Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant
Y. Lu,¹ J. Lyons,² S. Tischer,² K. Woodside,³ J. Park.²
¹Transplant Nephrology, University of Michigan, Ann Arbor, MI; ²Transplant Pharmacy, University of Michigan, Ann Arbor, MI; ³Transplant Surgery, University of Michigan, Ann Arbor, MI.
Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…
2018 American Transplant Congress
Mycophenolate Monotherapy is Safe and Effective in HLA-Matched Kidney Transplant Recipients
A. Hennes, K. Holdener, W. Burlingham, B. Astor, A. Djamali.
UW Health, Madison, WI.
Purpose: The ideal minimizing strategy for maintenance immunosuppression in HLA-matched kidney transplant recipients (KTR) is unknown. We hypothesized that mycophenolate (MPA) monotherapy is a safe…
2018 American Transplant Congress
Evaluation of Survival and Maintenance Immunosuppression in Elderly Lung Transplant Recipients
P. Nguyen,¹ R. Girgis,^1,2 E. Murphy,^1,2 R. Hadley,^1,2 M. Leacche,^1,2 A. Kumar,^1,2 G. Sathiyamoorthy,^1,2 J. McDermott.^1,2
¹Spectrum Health, Grand Rapids, MI; ²Michigan State University College of Human Medicine, Grand Rapids, MI.
Background: Lung transplantation in the elderly is controversial given increased risks and the optimal immunosuppression regimen is not fully understood.Methods: A retrospective cohort study was…
2018 American Transplant Congress
Immune Modulatory Effect of Thalidomide and Dexamethasone Co-Treatment on Murine Splenocytes
E. Kim,^1,2 J. Kim,¹ K. Huh,^1,3 Y. Cho,¹ M. Kim,^1,3 Y. Kim,^1,3 B. Kim.^1,4
¹The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea; ²Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea; ³Department of Transplantation Surgery, Yonsei University College of Medicine, Seoul, Korea; ⁴Department of Internal Medicine, Nephrology, Yonsei University College of Medicine, Seoul, Korea.
Thalidomide (TM) is known to have anti-inflammatory effects and dexamethasone (DX) is also well known to reduce inflammation and inhibit inflammatory cytokine production. Clinically, combinatorial…
2018 American Transplant Congress
Steroid Sparing Maintenance Immunosuppression is Associated with Decreased Mortality after Simultaneous Liver Kidney Transplantation
S. Weeks, X. Luo, C. Song, L. Pote, A. Gurakar, F. Navqi, B. Philosophe, A. Cameron, N. Desai, S. Ottmann, D. Segev, J. Garonzik Wang.
Johns Hopkins, Baltimore, MD.
Purpose: Significant variation in maintenance immunosuppression (mIS) regimens has been described between transplant centers for simultaneous liver kidney (SLK) transplant recipients; we sought to describe…
2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…
2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
A. Sharfuddin, M. Yaqub, D. Mishler, W. Goggins, T. Taber, O. Adebiyi.
Division of Renal Disease and Hypertension, Indiana University Health Transplant Program, Indianapolis, IN.
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…
2018 American Transplant Congress
Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study
J. Motter,¹ A. Massie,¹ J. Garonzik Wang,¹ K. Jackson,¹ X. Luo,¹ A. Muzaale,¹ B. Orandi,² D. Segev.¹
¹JHU, Baltimore; ²UCSF, San Francisco.
Background: Many patients with a willing, but incompatible live donor choose to undergo incompatible live donor kidney transplantation (ILDKT) facilitated by desensitization procedures to eliminate…